re: ASLAN
This is a pretty high-powered team.
Our Team
Dr Carl Firth
Chief Executive Officer
Dr Carl Firth is CEO and Founder of ASLAN Pharmaceuticals. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions.
Prior to joining the banking industry, he worked in China and Asia for 4 years leading business development, strategic projects and the development of new products. Carl has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence, and has over 5 years of pharmaceutical R&D experience.
Carl holds a PhD from Cambridge University in Molecular Biology and an Executive MBA from London Business School.
Dr Alan Barge
Chief Medical Officer
Dr Alan Barge is Chief Medical Officer for ASLAN Pharmaceuticals. Previously, Alan was VP of Clinical and Head of Oncology and Infection at AstraZeneca, responsible for building and managing a large development group, and the execution of the oncology portfolio globally over the last 5 years. Prior to that, Alan was responsible for early phase oncology development. During these 7 years, he was responsible for the re-focusing of the development, and registration of Iressa in Asia and Europe. Before joining AstraZeneca, Alan spent 8 years at Amgen as European Medical Director, and was responsible for the European, and subsequently Worldwide development of Neupogen and other compounds.
Alan trained in medicine at Oxford and London, and specialised in haematology and oncology, completing research and clinical fellowships in Seattle.
Dr Mark McHale
Chief Scientific Officer
Dr Mark McHale is Chief Scientific Officer and Founder of ASLAN Pharmaceuticals. Previously, Mark was the Head of Molecular Sciences at AstraZeneca Respiratory & Inflammation and in this role supported small molecule and therapeutic antibody projects from target identification to phase IIa. Mark was a core member of the respiratory strategy team for the the research area (comprising 720 staff across 3 sites) for half a decade and personally lead all new target identification in asthma. In 2006, he led a $136M investment in the AZ/Dynavax collaboration to produce inhaled TLR9 agonists for the treatment of asthma and led the ongoing preclinical / phase I projects.
Prior to 2001, Mark worked for 7 years at SmithKline Beecham, where he supported lead optimisation projects in serotonin and dopamine receptors as well as working on leptin and the PPAR gamma agonist Avandia with Dr Steve Smith. In 1994, he transferred to the Neuroscience Department working with Dr Jackie Hunter, during which time he set up two new molecular science laboratories and formed a successful team to support molecular analysis of stroke and pain in order to characterise disease and identify new targets from a large strategic collaboration SmithKline had initiated with Human Genome Sciences.
Mark trained at the University of London and University of East Anglia UK in Molecular Biology.
Bladerunner
Market Data 
Markets 
AI
